Stock Scorecard
Stock Summary for Clene Inc (CLNN) - $7.22 as of 12/3/2025 8:24:24 PM EST
Total Score
6 out of 30
Safety Score
34 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CLNN
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CLNN
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CLNN
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CLNN
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CLNN (34 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CLNN
Financial Details for CLNN
Company Overview |
|
|---|---|
| Ticker | CLNN |
| Company Name | Clene Inc |
| Country | USA |
| Description | Clene Inc. is a pioneering clinical-stage pharmaceutical company based in Salt Lake City, Utah, dedicated to developing innovative clean-surface nanotechnology (CSN) therapies targeting neurodegenerative diseases and other significant health challenges. With a commitment to conducting thorough clinical trials, Clene aims to secure regulatory approvals for its promising product pipeline, positioning itself as a potential leader in the biopharmaceutical sector. The company’s strong scientific foundation and forward-looking strategy align well with the interests of institutional investors seeking growth opportunities in the evolving healthcare landscape. |
| Sector Name | CONSUMER DEFENSIVE |
| Industry Name | PACKAGED FOODS |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 7.22 |
| Price 4 Years Ago | 82.00 |
| Last Day Price Updated | 12/3/2025 8:24:24 PM EST |
| Last Day Volume | 3,438,719 |
| Average Daily Volume | 224,975 |
| 52-Week High | 13.50 |
| 52-Week Low | 2.28 |
| Last Price to 52 Week Low | 216.67% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.93 |
| Sector PE | 28.77 |
| 5-Year Average PE | -53.96 |
| Free Cash Flow Ratio | 9.38 |
| Industry Free Cash Flow Ratio | 64.33 |
| Sector Free Cash Flow Ratio | 41.78 |
| Current Ratio Most Recent Quarter | 1.53 |
| Total Cash Per Share | 0.77 |
| Book Value Per Share Most Recent Quarter | -1.21 |
| Price to Book Ratio | 7.83 |
| Industry Price to Book Ratio | 2.00 |
| Sector Price to Book Ratio | 4.74 |
| Price to Sales Ratio Twelve Trailing Months | 447.16 |
| Industry Price to Sales Ratio Twelve Trailing Months | 1.04 |
| Sector Price to Sales Ratio Twelve Trailing Months | 1.45 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 10,334,000 |
| Market Capitalization | 74,611,480 |
| Institutional Ownership | 17.95% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 61.40% |
| Annual Earnings Growth | 20.41% |
| Reported EPS 12 Trailing Months | -3.23 |
| Reported EPS Past Year | -1.89 |
| Reported EPS Prior Year | -3.62 |
| Net Income Twelve Trailing Months | -30,496,000 |
| Net Income Past Year | -39,400,000 |
| Net Income Prior Year | -49,504,000 |
| Quarterly Revenue Growth YOY | -82.80% |
| 5-Year Revenue Growth | 46.97% |
| Operating Margin Twelve Trailing Months | -37,653.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 7,925,000 |
| Total Cash Past Year | 12,155,000 |
| Total Cash Prior Year | 28,821,000 |
| Net Cash Position Most Recent Quarter | -7,860,000 |
| Net Cash Position Past Year | -3,271,000 |
| Long Term Debt Past Year | 15,426,000 |
| Long Term Debt Prior Year | 7,152,000 |
| Total Debt Most Recent Quarter | 15,785,000 |
| Equity to Debt Ratio Past Year | -1.35 |
| Equity to Debt Ratio Most Recent Quarter | -3.60 |
| Total Stockholder Equity Past Year | -8,857,000 |
| Total Stockholder Equity Prior Year | 13,390,000 |
| Total Stockholder Equity Most Recent Quarter | -12,357,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -18,607,109 |
| Free Cash Flow Per Share Twelve Trailing Months | -1.80 |
| Free Cash Flow Past Year | -21,341,000 |
| Free Cash Flow Prior Year | -30,501,000 |
Options |
|
| Put/Call Ratio | 5.50 |
| Has Options | False |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.20 |
| MACD Signal | 0.19 |
| 20-Day Bollinger Lower Band | 2.06 |
| 20-Day Bollinger Middle Band | 7.16 |
| 20-Day Bollinger Upper Band | 12.25 |
| Beta | 0.77 |
| RSI | 50.62 |
| 50-Day SMA | 9.59 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 19.48 |
System |
|
| Modified | 12/3/2025 8:24:25 PM EST |